Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.52 |
| ▸ | GABRD | O14764 | 2/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.52 |
| ▸ | GABRE | P78334 | 2/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.52 |
| ▸ | NNMT | P40261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4394620 | 0.98 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL312493 | 0.84 | HDAC1 (0.61) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14214692 | 0.78 | DGAT1 (0.50) | SMN1; SMN2GAA | |
| SCHEMBL8483127 | 0.76 | HDAC1 (0.72) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2849627 | 0.75 | MPO (0.39) | KDM4EALDH1A1HSD17B10MASP2PLAU | |
| SCHEMBL20601155 | 0.72 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11839172 | 0.72 | PLAU (0.54) | SMN1; SMN2KDM4EALDH1A1HSD17B10MASP2 | |
| SCHEMBL2442493 | 0.71 | GABRP (0.67) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL19508992 | 0.71 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4403658 | 0.71 | GABRP (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645776-B2 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | CPT1A, CPT1B, CPT2 | GABRP 2343/4885GABRD 3270/4885GABRA1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.